Osimertinib Active Not Recruiting Phase 2 Trials for Neoplasms, Lung / EGFR Gene Mutations Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02769286Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA